Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma

MicroRNAs (MiRNAs) carried by exosomes play pivotal roles in the crosstalk between cell components in the tumor microenvironment. Our study aimed at identifying the expression profile of exosomal miRNAs (exo-miRNAs) in the serum of multiple myeloma (MM) patients and investigating the regulation networks and their potential functions by integrated bioinformatics analysis. Exosomes in serum from 19 newly diagnosed MM patients and 9 healthy donors were isolated and the miRNA profile was investigated by small RNA sequencing. Differential expression of exo-miRNAs was calculated and target genes of miRNAs were predicted. CytoHubba was applied to identify the hub miRNAs and core target genes. The LASSO Cox regression model was used to develop the prognostic model, and the ESTIMATE immune score was calculated to investigate the correlation between the model and immune status in MM patients. The top six hub differentially expressed serum exo-miRNAs were identified. 513 target genes of the six hub exo-miRNAs were confirmed to be differentially expressed in MM cells in the Zhan Myeloma microarray dataset. Functional enrichment analysis indicated that these target genes were mainly involved in mRNA splicing, cellular response to stress, and deubiquitination. 13 core exo-miRNA target genes were applied to create a novel prognostic signature to provide risk stratification for MM patients, which is associated with the immune microenvironment of MM patients. Our study comprehensively investigated the exo-miRNA profiles in MM patients. A novel prognostic signature was constructed to facilitate the risk stratification of MM patients with distinct outcomes.

[1]  K. Anderson,et al.  Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma , 2022, EBioMedicine.

[2]  C. Gu,et al.  YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis , 2022, Oncogene.

[3]  Yan Zhao,et al.  The Role of N6-Methyladenosine (m6A) Methylation Modifications in Hematological Malignancies , 2022, Cancers.

[4]  R. Liu,et al.  Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma , 2021, Frontiers in Oncology.

[5]  M. Dimopoulos,et al.  Metabolic Disorders in Multiple Myeloma , 2021, International journal of molecular sciences.

[6]  N. Munshi,et al.  Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment , 2021, Haematologica.

[7]  M. Beksac,et al.  HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA , 2021, Journal of Hematology & Oncology.

[8]  J. Martínez-López,et al.  The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression , 2021, Cancers.

[9]  Xiaoke Ma,et al.  Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment , 2020, Scientific Reports.

[10]  Tianzeng Chen,et al.  Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment , 2020, Frontiers in Oncology.

[11]  David J. Reiss,et al.  Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials , 2020, PLoS medicine.

[12]  Yong Chen,et al.  CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma. , 2020, Life sciences.

[13]  F. Zhan,et al.  Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a , 2020, Molecular Cancer Research.

[14]  J. Valcárcel,et al.  Roles and mechanisms of alternative splicing in cancer — implications for care , 2020, Nature Reviews Clinical Oncology.

[15]  T. Kouzarides,et al.  Role of RNA modifications in cancer , 2020, Nature Reviews Cancer.

[16]  G. Morgan,et al.  Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. , 2020, Haematologica.

[17]  H. Auner,et al.  Proteasome inhibition in multiple myeloma - lessons for other cancers. , 2019, American journal of physiology. Cell physiology.

[18]  A. Belli,et al.  Small Non-coding RNAs: New Class of Biomarkers and Potential Therapeutic Targets in Neurodegenerative Disease , 2019, Front. Genet..

[19]  N. Kosaka,et al.  A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma , 2018, Journal of clinical medicine.

[20]  Graça Raposo,et al.  Shedding light on the cell biology of extracellular vesicles , 2018, Nature Reviews Molecular Cell Biology.

[21]  S. Linder,et al.  Proteasome-associated deubiquitinases and cancer , 2017, Cancer and Metastasis Reviews.

[22]  Libing Song,et al.  Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma , 2017, Molecular Cancer.

[23]  L. Trippa,et al.  Prognostic role of circulating exosomal miRNAs in multiple myeloma. , 2017, Blood.

[24]  F. Zhan,et al.  NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma , 2017, Leukemia.

[25]  T. Whiteside,et al.  The emerging roles of tumor-derived exosomes in hematological malignancies , 2017, Leukemia.

[26]  Shouhao Zhou,et al.  Immune modulatory nanoparticle therapeutics for intracerebral glioma , 2016, Neuro-oncology.

[27]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[28]  Meng Chen,et al.  Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma , 2016, Oncotarget.

[29]  Clotilde Théry,et al.  Communication by Extracellular Vesicles: Where We Are and Where We Need to Go , 2016, Cell.

[30]  S. Buus,et al.  HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma , 2015, British Journal of Cancer.

[31]  P. Tassone,et al.  Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts , 2015, Oncotarget.

[32]  D. Rio,et al.  Mechanisms and Regulation of Alternative Pre-mRNA Splicing. , 2015, Annual review of biochemistry.

[33]  W. Zhang,et al.  ErbB2-intronic MicroRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling , 2015, Cell Death and Disease.

[34]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[35]  L. O’Driscoll,et al.  Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.

[36]  G. Görgün,et al.  Targeting the bone marrow microenvironment in multiple myeloma , 2015, Immunological reviews.

[37]  B. Seliger.  The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors , 2014, Journal of immunotoxicology.

[38]  K. Anderson,et al.  MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib , 2014, Leukemia.

[39]  Ting-Ting Huang,et al.  Interplay between microRNAs and the STAT3 signaling pathway in human cancers. , 2013, Physiological genomics.

[40]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[41]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[42]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[43]  Hong Chang,et al.  Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells , 2011, Journal of hematology & oncology.

[44]  Sebastian D. Mackowiak,et al.  miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.

[45]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[46]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[47]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[48]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[49]  Sun Mi Park,et al.  MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death , 2008, Oncogene.

[50]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[51]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[52]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[53]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[54]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[55]  Xueyan Chen,et al.  LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis. , 2019, American journal of translational research.

[56]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[57]  K. Anderson,et al.  MiR-29 b replacement inhibits proteasomes and disrupts aggresome + autophagosome formation to enhance the antimyeloma bene fi t of bortezomib , 2015 .